Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01078922 · ClinicalTrials.gov registry record · Phase 2
Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas
A Phase 2 study, sponsored by Oncology Specialists, S.C..
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01078922 is a Phase 2 study that was terminated before completion, run by Oncology Specialists, S.C.. The registered enrollment target is 11 participants.
The verdict
NCT01078922, a Phase 2 study, was terminated before completion, sponsored by Oncology Specialists, S.C..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is a phase II open label study that looks at the efficacy and toxicity of Ofatumumab monotherapy in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). Patients will receive weekly infusions of Ofatumumab of 1000 mg each for 8 weeks (induction phase) followed by continuing the study drugs every other week in subsequent cycles (maintenance phase). Each 4 weeks of therapy will be calculated as one cycle. Treatment will continue until disease progression, toxicity, patient's withdrawal, or investigator's discretion.
Interventions
- DRUG Ofatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-02 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01078922
The ClinicalTrials.gov registry entry for NCT01078922 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oncology Specialists, S.C., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ofatumumab is the first listed.
NCT01078922 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01078922 about?
NCT01078922 is a clinical study titled "Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin Lymphomas". This is a phase II open label study that looks at the efficacy and toxicity of Ofatumumab monotherapy in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL). Patients will receive weekly infusions of Ofatumumab of 1000 mg each for 8 weeks (induction phase) followed by cont...
What is the current status of trial NCT01078922?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2010-02. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01078922?
The interventions under investigation include: Ofatumumab (DRUG).
Who is sponsoring clinical trial NCT01078922?
This trial is sponsored by Oncology Specialists, S.C., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.